SCHEMBL23328249

SCHEMBL23328249

CN(C)C(=O)N1CCN(c2ccc(C(C)(C)C)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
HTT P42858 2/20 0.56
MAPT P10636 3/20 0.54
MAPK1 P28482 2/20 0.54
USP2 O75604 1/20 0.54
TP53 P04637 1/20 0.54
HSD17B10 Q99714 1/20 0.54
NPC1 O15118 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CA12 O43570 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
CA1 P00915 1/20 0.50
LMNA P02545 2/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
GFER P55789 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD11B1 P28845 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL270845 0.82 MAPT (0.74) ALDH1A1KDM4EHTTMAPTMAPK1
SCHEMBL22542064 0.82 AKR1C3 (0.59) ALDH1A1KDM4EHTTMAPTUSP2
SCHEMBL6150875 0.81 GFER (0.68) ALDH1A1KDM4EHTTMAPTMAPK1
SCHEMBL30508269 0.81 AKR1C3 (0.58) ALDH1A1MAPTUSP2LMNAMEN1
SCHEMBL1811256 0.81 GFER (0.68) ALDH1A1KDM4EHTTMAPTMAPK1
SCHEMBL11916169 0.81 MAPT (0.54) ALDH1A1KDM4EHTTMAPTMAPK1
SCHEMBL11048879 0.80 HRH3 (0.59) ALDH1A1HTTMAPTMAPK1USP2
SCHEMBL1483601 0.79 MAPT (0.63) ALDH1A1KDM4EHTTMAPTMAPK1
SCHEMBL20883570 0.79 PANK3 (0.56) ALDH1A1KDM4EHTTMAPTMAPK1
SCHEMBL20178041 0.79 HSD11B1 (0.57) ALDH1A1KDM4EHTTMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 ALDH1A1 748/4885KDM4E 1695/4885HTT 3713/4885
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF FGFR1, FGFR4, FGFR2 ALDH1A1 642/4885KDM4E 1724/4885HTT 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.